|
|
Article: Massachusetts General Hospital and Idera Pharmaceuticals Receive Cooperative Research Grant from Massachusetts Life Sciences Center for Developing New Therapies for Lupus.
- Article from:
- Business Wire
- Article date:
- December 22, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOSTON & CAMBRIDGE, Mass. -- Dr. Andrew Luster, Chief of the Division of Rheumatology, Allergy, and Immunology at Massachusetts General Hospital (MGH), and Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a drug discovery and development company focused on therapeutics targeting Toll-like Receptors (TLR), have received a Cooperative Research Grant from the Massachusetts Life Sciences Center (MLSC). Under the collaboration between Dr. Luster and Idera, Idera's novel TLR antagonist candidates will be studied as potential therapeutic agents for autoimmune diseases such as lupus.
"The funding awarded by the MLSC to MGH, and the funding from Idera under our collaboration, ...